a2b

A2B receptor antagonist 1 (EXAMPLE 9B) is a potent A2B adenosine receptor antagonist.

A2B receptor antagonist 2 is an antagonist of adenosine receptor A2B (Ki = 2.30 μM for rA1, 6.8 μM for rA2A, 3.44 μM for hA2B).

BAY 60-6583 is a potent, high-affinity adenosine A2B receptor agonist (EC50 = 3 nM) with affinity for A2B receptors that exceeds that for A1, A2A, and A3 receptors.BAY 60-6583 is cardioprotective in a model of myocardial ischemia.The Ki values for BAY 60-6583 binding to mouse, rabbit, and dog A2BAR were 750 nM, 340 nM, and 330 nM, respectively. The Ki values of BAY 60-6583 binding to A2BAR in mice, rabbits and dogs were 750 nM, 340 nM and 330 nM respectively.

GS-6201 (CVT-6883) is a selective antagonist of the adenosine A2B receptor, demonstrating high affinity and selectivity with a Ki of 22 nM for human adenosine A2B receptors.

LAS101057 is a novel orally available and potent and selective A2B receptor antagonist for the study of asthma.

MRS 1754 is a selective antagonist radioligand for the A2B adenosine receptor, exhibiting very low affinity for A1 and A3 receptors in both humans and rats.

Alloxazine (Isoalloxazine) is an A2 receptor antagonist, which is approximately 10-fold more selective for the A2B receptor than for the A2A receptor.

AB928 is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist. It has immunomodulatory activity[1].

CGS 15943 is an orally bioavailable non-xanthine antagonist of the Adenosine Receptor. In transfected CHO cells, its Ki values for human A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2, 16, and 50 nM, respectively.

MRS-1706 has Ki values of 1.39, 112, 157, and 230 nM for human A2B, A2A, A1, and A3 receptors respectively. MRS-1706 is an effective and selective adenosine A2B receptor inverse agonist.

PSB-603 is a selective antagonist of Adenosine A2B receptor(Ki = 0.553 nM) with anti-inflammatory effects.

BAY-545 is an antagonist of A2B adenosine receptor(IC50 : 59 nM).

1-Ethyl-6-aminouracil (6-AMINO-1-ETHYL-1H-PYRIMIDINE-2,4-DIONE) is an intermediate in the synthesis of a series of new substituted Xanthines which have high affinity and selectivity for the human adenosine A2B receptors.

A2B receptor antagonist 2 hydrochloride is an antagonist of adenosine receptor A2B (Ki = 2.30 μM for rA1, 6.8 μM for rA2A, 3.44 μM for hA2B).

A2AR/A2BR antagonist 1 (compound 7ai) acts as a dual antagonist to A2AR and A2BR with IC50 values of 11.2 nM and 6.4 nM, respectively. Additionally, A2AR/A2BR antagonist 1 enhances T cell-mediated cancer cell death.

A2B57 is a selective SIRT2 inhibitor.

FA2B glycan (G0B), 2-AA labelled (FA2B N-linked oligosaccharide, 2-AA labelled; G0F with bisecting GlcNAc, 2-AA labelled) is a multi-functional fluorescent linker consisting of a polymeric N-glycoprotein. The resultant conjugates mimic the antennal elements of N-glycans, offering high sensitivity and specificity.

FA2B glycan (G0B), 2-AB labelled (FA2B N-linked oligosaccharide, 2-AB labelled; G0F with bisecting GlcNAc, 2-AB labelled), is a versatile fluorescent linker and a type of poly N-glycoprotein. The resulting conjugates exhibit high sensitivity and specificity by mimicking the antenna structure of N-glycans.

human A2B adenosine receptor antagonist

LAS38096 is an A2B adenosine receptor antagonist (Ki : 17 nM) that is potent, selective and efficient .

Sonedenoson (MRE0094) is an adenosine A(2A) receptor agonist and potential inhibitor potentially targeting SARS-CoV-2 coronavirus 2;-O-ribose methyltransferase, and may be used in the study of diabetic foot ulcers.

ISAM-140 is a potent and highly selective antagonist of A2B adenosine receptor.

ATL444 is an adenosine receptor antagonist with affinity (Ki values) for rA1AR, rA2AAR, rA2BAR, and rA3AR of 7.0, 2.5, 61.8, and >1000 nM, respectively.

Adenosine receptor agonist2 (Compound 10) is an agonist of the adenosine A2B receptor (A2BR) with an EC50 of 0.38 nM. It significantly inhibits the accumulation of cAMP and calcium ions. Adenosine receptor agonist2 is applicable in cardiovascular protection studies.